Hanke Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hanke Ma has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Liping Dai
Henan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, China
9 shared publications - Aichen Liu
Henan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, China
8 shared publications - Fengqi Chen
Henan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, China
8 shared publications - Jingjing Liu
Henan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, China
8 shared publications - Lulu Zhang
Henan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, China
8 shared publications - Siyu Liu
Henan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, China
8 shared publications
Latest Publications
- Open Access
- 17 February 2026
- Published by Wiley in Cancer Science
- Vol. 117 (5) , 1244-1259
The Overlooked Autoantibody Repertoire: Exploring the Biomarker Potential of Downregulated Autoantibodies in NSCLC
Autoantibodies (AAbs) represent promising biomarkers in cancer. While most AAbs are elevated in cancer, a substantial subset is downregulated, and their diagnostic and prognostic potential remains largely unexplored. Here we used the HuProt protein microarray to identify downregulated AAbs in non‐small cell lung cancer (NSCLC) serum. Indirect ELISA quantified serum levels in 781 samples. Ten machine learning algorithms were used to construct diagnostic models. An independent cohort of 353 NSCLC patients was used to assess prognostic value and develop a prognostic model. Six downregulated AAbs were identified, among which five AAbs (anti‐HIST1H1B, anti‐HIST1H1C, anti‐DYDC2, anti‐CAMKK2, and anti‐GRPEL1) were significantly reduced in NSCLC. The gradient boosting machine (GBM) model showed the best performance for NSCLC and BPNs, with AUCs of 0.869 (95% CI: 0.833–0.905) in the training set and 0.813 (95% CI: 0.745–0.880) in the validation set. For early‐stage NSCLC, the model achieved an AUC of 0.809 (95% CI: 0.729–0.890) in the validation set, with a sensitivity of 74.0% and specificity of 81.3%. Multivariate Cox regression identified four AAbs significantly associated with patient prognosis. A prognostic model integrating age and AAb levels demonstrated robust predictive performance for long‐term survival (7‐year AUC = 0.79). Bioinformatics analyses further supported the relevance of the corresponding genes/proteins of these AAbs to NSCLC outcomes. Overall, our findings demonstrate that downregulated AAbs possess significant diagnostic and prognostic value in NSCLC and may contribute to improved patient management and survival prediction.
- 17 February 2026
- Published by Wiley in Cancer Science
- Vol. 117 (5) , 1244-1259
Open AccessThe Overlooked Autoantibody Repertoire: Exploring the Biomarker Potential of Downregulated Autoantibodies in NSCLC
Autoantibodies (AAbs) represent promising biomarkers in cancer. While most AAbs are elevated in cancer, a substantial subset is downregulated, and their diagnostic and prognostic potential remains largely unexplored. Here we used the HuProt protein microarray to identify downregulated AAbs in non‐small cell lung cancer (NSCLC) serum. Indirect ELISA quantified serum levels in 781 samples. Ten machine learning algorithms were used to construct diagnostic models. An independent cohort of 353 NSCLC patients was used to assess prognostic value and develop a prognostic model. Six downregulated AAbs were identified, among which five AAbs (anti‐HIST1H1B, anti‐HIST1H1C, anti‐DYDC2, anti‐CAMKK2, and anti‐GRPEL1) were significantly reduced in NSCLC. The gradient boosting machine (GBM) model showed the best performance for NSCLC and BPNs, with AUCs of 0.869 (95% CI: 0.833–0.905) in the training set and 0.813 (95% CI: 0.745–0.880) in the validation set. For early‐stage NSCLC, the model achieved an AUC of 0.809 (95% CI: 0.729–0.890) in the validation set, with a sensitivity of 74.0% and specificity of 81.3%. Multivariate Cox regression identified four AAbs significantly associated with patient prognosis. A prognostic model integrating age and AAb levels demonstrated robust predictive performance for long‐term survival (7‐year AUC = 0.79). Bioinformatics analyses further supported the relevance of the corresponding genes/proteins of these AAbs to NSCLC outcomes. Overall, our findings demonstrate that downregulated AAbs possess significant diagnostic and prognostic value in NSCLC and may contribute to improved patient management and survival prediction.
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Supplementary Figure S3 shows the ROC curve analysis of anti-FDX1 autoantibody in different clinical subgroups of NSCLC versus BPN
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Supplementary Figure S3 shows the ROC curve analysis of anti-FDX1 autoantibody in different clinical subgroups of NSCLC versus BPN
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Supplementary Figure S1 shows the protein expression level of FDX1 in A549 and PC-9 cells by western blotting analysis.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Supplementary Figure S1 shows the protein expression level of FDX1 in A549 and PC-9 cells by western blotting analysis.
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Supplementary Figure S2 shows the ROC curve analysis of anti-FDX1 autoantibody in different clinical subgroups of NSCLC versus NC.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Supplementary Figure S2 shows the ROC curve analysis of anti-FDX1 autoantibody in different clinical subgroups of NSCLC versus NC.
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Supplementary Figure S4 shows the mRNA expression level of FDX1 in LUAD and LUSC patients based on GEPIA database.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Supplementary Figure S4 shows the mRNA expression level of FDX1 in LUAD and LUSC patients based on GEPIA database.
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Supplementary Table S1 shows the characterization of all participants.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Supplementary Table S1 shows the characterization of all participants.
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Supplementary Table S2 shows the combination analysis of anti–FDX1 autoantibody and CEA to distinguish NSCLC.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Supplementary Table S2 shows the combination analysis of anti–FDX1 autoantibody and CEA to distinguish NSCLC.
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Data from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Background:Autoantibodies can be readily identified prior to biopsy and may serve as valuable biomarkers for cancer detection. Ferredoxin 1 (FDX1) is a key regulator in the process of cuproptosis and affects the prognosis of lung cancer. In this study, we investigated whether the anti-FDX1 autoantibody could serve as a novel biomarker for the detection of non–small cell lung cancer (NSCLC).Methods:A total of 1,155 plasma samples were divided into the verification and validation groups. The expression levels of the anti-FDX1 autoantibody in 414 patients with NSCLC, 327 patients with benign pulmonary nodules (BPN), and 414 normal controls (NC) were detected using ELISA. Western blotting and immunofluorescence analyses were performed to confirm the ELISA results.Results:Plasma anti-FDX1 autoantibody levels were significantly higher in patients with NSCLC than in patients with BPN and NCs in the verification and validation groups. The ELISA results were confirmed by Western blotting and immunofluorescence. The anti-FDX1 autoantibody distinguished NSCLC from NC and BPN with an AUC (95% confidence interval) of 0.806 (0.772–0.839) and 0.627 (0.584–0.670), respectively.Conclusions:Our study demonstrated the potential benefits of the anti-FDX1 autoantibody as a novel biomarker for NSCLC detection.Impact:These findings suggested that the anti-FDX1 autoantibody may facilitate the detection of NSCLC.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Background:Autoantibodies can be readily identified prior to biopsy and may serve as valuable biomarkers for cancer detection. Ferredoxin 1 (FDX1) is a key regulator in the process of cuproptosis and affects the prognosis of lung cancer. In this study, we investigated whether the anti-FDX1 autoantibody could serve as a novel biomarker for the detection of non–small cell lung cancer (NSCLC).Methods:A total of 1,155 plasma samples were divided into the verification and validation groups. The expression levels of the anti-FDX1 autoantibody in 414 patients with NSCLC, 327 patients with benign pulmonary nodules (BPN), and 414 normal controls (NC) were detected using ELISA. Western blotting and immunofluorescence analyses were performed to confirm the ELISA results.Results:Plasma anti-FDX1 autoantibody levels were significantly higher in patients with NSCLC than in patients with BPN and NCs in the verification and validation groups. The ELISA results were confirmed by Western blotting and immunofluorescence. The anti-FDX1 autoantibody distinguished NSCLC from NC and BPN with an AUC (95% confidence interval) of 0.806 (0.772–0.839) and 0.627 (0.584–0.670), respectively.Conclusions:Our study demonstrated the potential benefits of the anti-FDX1 autoantibody as a novel biomarker for NSCLC detection.Impact:These findings suggested that the anti-FDX1 autoantibody may facilitate the detection of NSCLC.
- 19 December 2024
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (3) , 439-447
Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Background: Autoantibodies can be readily identified prior to biopsy and may serve as valuable biomarkers for cancer detection. Ferredoxin 1 (FDX1) is a key regulator in the process of cuproptosis and affects the prognosis of lung cancer. In this study, we investigated whether the anti-FDX1 autoantibody could serve as a novel biomarker for the detection of non–small cell lung cancer (NSCLC). Methods: A total of 1,155 plasma samples were divided into the verification and validation groups. The expression levels of the anti-FDX1 autoantibody in 414 patients with NSCLC, 327 patients with benign pulmonary nodules (BPN), and 414 normal controls (NC) were detected using ELISA. Western blotting and immunofluorescence analyses were performed to confirm the ELISA results. Results: Plasma anti-FDX1 autoantibody levels were significantly higher in patients with NSCLC than in patients with BPN and NCs in the verification and validation groups. The ELISA results were confirmed by Western blotting and immunofluorescence. The anti-FDX1 autoantibody distinguished NSCLC from NC and BPN with an AUC (95% confidence interval) of 0.806 (0.772–0.839) and 0.627 (0.584–0.670), respectively. Conclusions: Our study demonstrated the potential benefits of the anti-FDX1 autoantibody as a novel biomarker for NSCLC detection. Impact: These findings suggested that the anti-FDX1 autoantibody may facilitate the detection of NSCLC.
- 19 December 2024
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (3) , 439-447
Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Background: Autoantibodies can be readily identified prior to biopsy and may serve as valuable biomarkers for cancer detection. Ferredoxin 1 (FDX1) is a key regulator in the process of cuproptosis and affects the prognosis of lung cancer. In this study, we investigated whether the anti-FDX1 autoantibody could serve as a novel biomarker for the detection of non–small cell lung cancer (NSCLC). Methods: A total of 1,155 plasma samples were divided into the verification and validation groups. The expression levels of the anti-FDX1 autoantibody in 414 patients with NSCLC, 327 patients with benign pulmonary nodules (BPN), and 414 normal controls (NC) were detected using ELISA. Western blotting and immunofluorescence analyses were performed to confirm the ELISA results. Results: Plasma anti-FDX1 autoantibody levels were significantly higher in patients with NSCLC than in patients with BPN and NCs in the verification and validation groups. The ELISA results were confirmed by Western blotting and immunofluorescence. The anti-FDX1 autoantibody distinguished NSCLC from NC and BPN with an AUC (95% confidence interval) of 0.806 (0.772–0.839) and 0.627 (0.584–0.670), respectively. Conclusions: Our study demonstrated the potential benefits of the anti-FDX1 autoantibody as a novel biomarker for NSCLC detection. Impact: These findings suggested that the anti-FDX1 autoantibody may facilitate the detection of NSCLC.